



ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION PRESENTS AT ASX SMALL AND MID-CAP CONFERENCE

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to provide a presentation to be given today by EMVision’s Managing Director and CEO, Dr Ron Weinberger to the ASX Small and Mid-cap Conference 2021.

Latest design and new developments of our planned device for commercialisation

Contained within the presentation is the latest design for EMVision’s 1st generation portable brain scanner intended for commercialisation, which, looking towards future road/air ambulance models, now incorporates a miniaturised Vector Network Analyser (VNA) within the headset.

Anatomical reconstructions of the brain using Electromagnetic (EM) Imaging

In addition, a promising new imaging technique is unveiled which enables anatomically correct structure and context, alongside functional imaging capabilities.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision’s Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision’s CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics’ (ASX:NAN), a \$1.9 billion market cap healthcare company. Dr Weinberger has over 25-years’ experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company’s platform technology and launched their breakthrough product ‘Tropon’ globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia’s leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.



ASX SMALL AND MID-CAP PRESENTATION

March 2021



ASX CODE	SHARES ON ISSUE	CASH BALANCE (31 DEC 2020)	ASA STAGED GRANT	52 WEEK HIGH	SHARE PRICE	MARKET CAPITALISATION	ENTERPRISE VALUE
ASX:EMV	70.7M	\$13M	\$8M	\$4.20	\$2.66*	\$188M*	\$175M*

* Undiluted market cap based on closing price of \$2.66 Friday 12th March 2021

DISCLAIMER


This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in EMVision in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors.

Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Similarly, past performance, including information concerning historical cash burn rates, should not be seen as indicative of future performance.

Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of EMVision. To the maximum extent permitted by law, EMVision and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

An investment in EMVision securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of EMVision. EMVision does not guarantee any rate of return or the absolute or relative investment performance of EMVision securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions.

TRANSFORMATIVE POINT-OF-CARE IMAGING



Video available at www.emvision.com.au

ADDRESSING ACCESSIBILITY

2/3rds of the world does not have access to diagnostic imaging.

LOW-COST HARDWARE

Energy emitted from a scan is **less than 1%** of energy emitted from a mobile phone. Does not emit harmful radiation. Less capital intensive to manufacture.

PLATFORM MODALITY

Applications across the entire body, targeting time sensitive neurological disorders first.

BRINGING IMAGING TO WHERE STROKE OCCURS WILL SAVE LIVES



STROKE IS A GLOBAL SOCIETAL & HEALTH ECONOMIC BURDEN




THERE ARE EFFECTIVE TREATMENTS AVAILABLE




THEY ARE TIME SENSITIVE



WHAT CLINICIANS NEED TO KNOW...



CLOT
(ISCHAEMIC)



BLEED
(HAEMORRHAGIC)

ACUTE ISCHAEMIC STROKE PATIENTS CAN BENEFIT FROM CLOT DISSOLVING DRUGS (tPA) IF GIVEN WITHIN HOURS, BUT THESE DRUGS WORSEN BLEEDING IF THE STROKE IS DUE TO A HAEMORRHAGE. THE ABILITY TO DISTINGUISH STROKE TYPE, SIZE AND LOCATION AT THE POINT OF CARE ARE SOME OF THE POTENTIAL UTILITIES OF THE EMVISION DEVICE.



1ST GENERATION DEVICE

Detect clinically significant changes, at the bedside, when time matters, before clinical symptoms present.



2ND GENERATION DEVICE


Ultra light weight device embedded in standard road and air ambulances to deliver pre-hospital stroke care to patients regardless of location.



AUSTRALIAN STROKE ALLIANCE COLLABORATION EMV TO RECEIVE \$8M NON-DILUTIVE STAGED FUNDING*


PRODUCT STREAM 1

FUNDING AND CLINICAL EXPERTISE FOR 1st GENERATION DEVICE PIVOTAL TRIALS & CLINICAL VALIDATION



PRODUCT STREAM 2

FUNDING AND CLINICAL EXPERTISE TO ADAPT AND VALIDATE EMVISION TECHNOLOGY FOR ROAD & AIR AMBULANCES



**Subject to conditions as per the Company's ASX announcement titled "Successful MRFF Bid" released on 2nd March 2021 for further details, which includes a summary of the conditions of the staged funding.
This is an artistic concept of a proposed first responder device which is subject to prototype development and clinical testing*

PILOT CLINICAL STUDY OVERVIEW

STUDY DESIGN

PILOT CLINICAL TRIAL

- The single-site study, at the Princess Alexandra Hospital (PAH) in Brisbane, of patients with diagnosed ischaemic or haemorrhagic stroke, is the first clinical study for EMVision's novel imaging technology.
- Patients were scanned with EMVision's device at close proximity to their standard of care imaging (CT and MRI)
- No intervention or modification to the standard of care of hospital-based treatment of stroke was done as part of this study.

PATIENT COHORT

30 STROKE PATIENTS ENROLLED


- The study enrolled and processed datasets from **30 patients (21 ischaemic and 9 haemorrhagic)** representing the diversity of stroke in localisation, size and clinical severity.
- The mean age was 66.7
- Of the 30 patients, 19, (63.3%) had only a CT performed whereas 11, (36.7%) had CT/MRI performed.
- The mean NIHSS score was calculated as 5.2 which indicates mild severity.

STUDY OBJECTIVE

PRIMARY END POINT ACHIEVED

- The primary endpoint was the collection of a dataset of stroke patients which improves the understanding of stroke on electromagnetic scattering effects in the brain. This end point has been met, producing datasets that have enabled EMVision to advance its imaging algorithm and hardware development.
- The dataset enabled an observation of the correlation of EMVision scans with patients' "ground truth" CT and/or MRI scans.

FUSION WITH CLASSIFIER - EXAMPLES




The above examples have been selected to demonstrate how the fusion methodology can be used to detect, localise, and classify stroke type and should be interpreted in light of the intent and results of this study to date.

FIRST ANATOMICAL DIELECTRIC ESTIMATION IMAGES USING NEURAL NETWORKS


A UNIQUE TECHNIQUE IS UNDER DEVELOPMENT TO AUGMENT EMVISION'S EXISTING IMAGING CAPABILITIES WITH ANATOMICALLY CORRECT INTERNAL TISSUE DISTRIBUTIONS AND THEIR DIELECTRIC PROPERTIES

STRONG POTENTIAL TO PROVIDE ADDITIONAL STRUCTURAL CLINICAL INFORMATION, CONTINUING TO BE EVALUATED AND VERIFIED AGAINST CLINICAL DATA

Patient Example from study



Ground Truth MRI Slice



ANATOMICAL DIELECTRIC MAP

- Gray Matter $\epsilon = 53$
Predicted Gray Matter $\epsilon = [48, 54]$
- White Matter $\epsilon = 39$
Predicted White Matter $\epsilon = [39, 42]$
- CSF $\epsilon = 70$
Predicted CSF $\epsilon = [69, 75]$
- Skin $\epsilon = 42$
Predicted Skin $\epsilon = [38, 44]$
- Skull $\epsilon = 10$
Predicted Skull $\epsilon = [3, 13]$
- Coupling Medium $\epsilon = 52$
Predicted Coupling Medium $\epsilon = [52, 53]$

The above examples have been selected to demonstrate how the neural network dielectric property estimate technique under development can be used to illustrate an anatomically correct permittivity map and should be interpreted in light of the intent and results of this study to date.

STUDY OUTCOMES & UPCOMING MILESTONES

93.3% - 96%*
ACCURACY

STROKE SUBTYPE CLASSIFICATION

Ability to distinguish between ischaemic and hemorrhagic stroke types

86.7% - 96%*
ACCURACY

LOCALISATION IN CORRECT QUADRANT

Comparable target localization with ground truth CT and MRI images

POSITIVE OPERATOR AND PATIENT FEEDBACK

Despite being a prototype, positive feedback on non-invasive nature of device

CY 2021 TARGET MILESTONES

CLINICAL TRIALS

Pivotal Clinical Trial Site Selection and Protocol Development

Pivotal Clinical Trial Site Contracts

Pivotal Clinical Trial initiation

20 additional patient datasets being collected with clinical prototype at PAH

Pivotal Clinical Trial Ethics Approval

DEVICE DEVELOPMENT

Design, development and fabrication of 1st gen commercial unit

Commence V&V, EMC, Safety & Healthy Volunteer Testing

Preparation for pilot manufacturing

REGULATORY

FDA Engagement (including Breakthrough Status Application)

Pivotal Clinical Trial protocol design and FDA feedback

FDA Breakthrough Application Outcome

ASA & COLLABORATIONS


ASA Contract finalisation and program planning

Commercial and Collaboration Updates

A larger dataset will be required to draw conclusions on sensitivity/specificity for blood and ischemia. The algorithms may be subject to further refinement and investors should note there is no guarantee the algorithms will replicate the same level of accuracy on larger data sets without further refinement, or at all. Five datasets where pathologies were estimated to fall outside of the anticipated prototype hardware range were identified and accuracy figures presented here are with, and without, the 5 excluded datasets for completeness. V&V: Verification and Validation, EMC: Electromagnetic Compatibility Testing, ASA: Australian Stroke Alliance. The indicative timetable is a guide of EMVision's intentions at the date of this presentation only. EMVision reserves the right to vary this timetable at its discretion, and further notes the above timings are subject to change due to circumstances outside of its control.

MORE LIVES COULD BE SAVED WITH A LIGHTWEIGHT SCALABLE IMAGING SOLUTION

Nearly 10x more patients treated within the “golden hour” (first 60 minutes) with Melbourne Mobile Stroke Unit



Mobile Stroke Unit (MSU)




Inside an MSU today

A Mobile Stroke Unit (MSU) today is a custom-built specialist Ambulance vehicle that houses a ~500kg CT scanner, specialized personnel and carries stroke treatment drugs, including blood clot-dissolving medications.



- Sites with active mobile stroke units
- ▲ Sites with MSU projects in planning or implementation state



EMV 2nd Gen

FLEXIBLE & ATTRACTIVE REVENUE MODELS

DIRECT OR DISTRIBUTOR

MONTHLY SUBSCRIPTION MODEL

- Delivery of the unit
- Training
- Software updates
- New algorithm sequences as they come out
- Potential integration into PACS and EMR
- Access to cloud storage and viewing
- Routine maintenance included



CAPITAL EQUIPMENT & CONSUMABLES MODEL




Device Sales



Consumables



Software



Maintenance & Service



STROKE WARDS, CRITICAL CARE UNITS & ED



US.



10,200

GER, FR, UK



5,960

AU



545

JAPAN



2,875

ROAD & AIR AMBULANCES

US.



60,000

EUROPE



58,000

AU



5,200



TEAM

Significant experience developing and commercialising medical devices



Dr Ron Weinberger
CEO & MD
Former Nanosonics MD
(ASX:NAN)



John Keep
Non-Executive Chairman
Former CEO Queensland Diagnostic
Imaging



Scott Kirkland
Executive Director
Co-Founder EMVision



Prof Stuart Crozier
Chief Scientific Officer
2/3rd MRIs use Prof Crozier
developed IP



Robert Tiller
Head of Design
Founder Tiller Design



Forough Khandan
Head of Program Management
Former Nanosonics Program
Manager



Geoff Pocock
Non-Executive Director
Former Hazer MD
(ASX:HZR)



Tony Keane
Non-Executive Director
National Storage NED
(ASX:NSR)



Dr Philip Dubois
Non-Executive Director
Neuroradiologist, Former
CEO, imaging division, Sonic
Healthcare Ltd (ASX:SHL)



Emma Waldon
Company Secretary
Capital markets and corporate
governance expert



Dr. Konstanty Bialkowski
Head of Tech Development
EM Imaging expert and Co-
Inventor



Ruth Cremin
*Head of Quality & Regulatory
Affairs*
Former Head of Regulatory
at Nanosonics

PARTNERS & COLLABORATORS



Commonwealth CRC-P Grant Program Collaborators

Product Collaboration

Clinical Development & Validation

CAPITAL STRUCTURE

Headquarters:
4.01, 65 Epping Road, Macquarie Park
Sydney, Australia

ASX TICKER: EMV

Share Price (12th March 2021) \$2.66 (AUD)

Shares on issue 70.7m

Total Options on issue ¹ 10.1m

Performance Rights² 6m

Cash Balance 31 Dec 20 **\$13.17m (AUD)**


Market Capitalization \$188m (AUD)

Enterprise Value \$175m (AUD)

MRFF Non-dilutive Grant Funds³ **\$8m (AUD)**



HISTORICAL CASH BURN



1 – See ASX release titled ‘Appendix 2A’ from 17th Dec 2020 for further information on Options 2 – All performance rights are held by UniQuest and will vest on particular milestones over time – further details in IPO prospectus | 3 – The Australian Stroke Alliance has advised EMVision that it will receive \$8m in non-dilutive cash funding towards product development and clinical validation, see ASX release titled ‘Successful MRFF Bid’ for further information and conditions of staged funding | Closing price 12th March 2021

EMVISION HISTORY

